Education
About Us
Working with TipRanks
Follow Us
Vaccinex (VCNX)
:VCNX
VCNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $8.90
Previous CloseN/A
Volume245.00
Average Volume (3M)958.00
Market Cap
$2.13M
Enterprise Value$21.25M
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta2.13
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.12
Shares Outstanding2,676,637
10 Day Avg. Volume517
30 Day Avg. Volume958
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap9.96
Enterprise Value/Revenue68.34
Enterprise Value/Gross Profit-6.46
Enterprise Value/Ebitda-0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vaccinex News
PremiumCompany Announcements
Vaccinex Delays Yearly Report Filing
Options Prices
Currently, No data available
---
Ownership Overview
51.26% Insiders
0.15% Mutual Funds
6.13% Other Institutional Investors
42.62% Public Companies and
Individual Investors
VCNX FAQ
What was Vaccinex’s price range in the past 12 months?
Vaccinex lowest stock price was $0.25 and its highest was $8.90 in the past 12 months.
What is Vaccinex’s market cap?
Vaccinex’s market cap is $2.13M.
When is Vaccinex’s upcoming earnings report date?
Vaccinex’s upcoming earnings report date is May 19, 2025 which is 26 days ago.
How were Vaccinex’s earnings last quarter?
Vaccinex released its earnings results on Mar 18, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.26.
Is Vaccinex overvalued?
According to Wall Street analysts Vaccinex’s price is currently Overvalued.
Does Vaccinex pay dividends?
Vaccinex does not currently pay dividends.
What is Vaccinex’s EPS estimate?
Vaccinex’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex have?
Vaccinex has 2,676,637 shares outstanding.
What happened to Vaccinex’s price movement after its last earnings report?
Vaccinex reported an EPS of -$1.26 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Vaccinex?
Currently, no hedge funds are holding shares in VCNX
Company Description
Vaccinex
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Technical Analysis
Scinai Immunotherapeutics
―
Qualigen Therapeutics
―
Nucana
―
CNS Pharmaceuticals
―
Galecto
―